The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.
A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer
Open accessAbstract
Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive disease to review and possibly improve therapeutic treatment options. Surgery, radiation, chemotherapy, targeted treatments, and immunotherapy separate or in combination are commonly used to treat lung cancer. However, these treatment types may cause different side effects, and chemotherapy-based regimens appear to have reached a therapeutic plateau. Hence, effective, better-tolerated treatments are needed to address and hopefully overcome this conundrum. Recent advances have enabled biologists to better investigate the potential use of natural compounds for the treatment or control of various cancerous diseases. For the past 30 years, natural compounds have been the pillar of chemotherapy. However, only a few compounds have been tested in cancerous patients and only partial evidence is available regarding their clinical effectiveness. Herein, we review the research on using current chemotherapy drugs and natural compounds (Wortmannin and Roscovitine, Cordyceps militaris, Resveratrol, OSU03013, Myricetin, Berberine, Antroquinonol) and the beneficial effects they have on various types of cancers including non-small cell lung cancer. Based on this literature review, we propose the use of these compounds along with chemotherapy drugs in patients with advanced and/or refractory solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis
Li, H., Zhu, H., Xu, C.-J., & Yuan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81590-1 · Cited by 4,445
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Winton, T., Livingston, R., Johnson, D., Rigas, J., Johnston, M., Butts, C., Cormier, Y., Goss, G., Inculet, R., Vallieres, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043623 · Cited by 1,810
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.
Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., & Takada, Y. (2004) · PubMed · Cited by 1,605
Molecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564
Estimates of the worldwide mortality from 25 cancers in 1990
Pisani, P., Parkin, D. M., Bray, F., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990924)83:1<18::aid-ijc5>3.0.co;2-m · Cited by 1,549
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Peto, R. (2000) · BMJ · doi:10.1136/bmj.321.7257.323 · Cited by 1,409
Meijer, L., Borgne, A., Mulner, O., Chong, J. P. J., Blow, J. J., Inagaki, N., Inagaki, M., Delcros, J., & Moulinoux, J. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-2-00527.x · Cited by 1,352
The new World Health Organization classification of lung tumours
Brambilla, E., Travis, W. D., Colby, T. V., Corrin, B., & Shimosato, Y. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00275301 · Cited by 1,131
Multidisciplinary Management of Lung Cancer
Spira, A., & Ettinger, D. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035536 · Cited by 922
Mechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Resveratrol: A molecule whose time has come? And gone?
Soleas, G. J., Diamandis, E. P., & Goldberg, D. M. (1997) · Clinical Biochemistry · doi:10.1016/s0009-9120(96)00155-5 · Cited by 849
Baselga, J., Rischin, D., Ranson, M., Calvert, H., Raymond, E., Kieback, D. G., Kaye, S. B., Gianni, L., Harris, A., Bjork, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.100 · Cited by 829
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Mineishi, S., Tarassoff, P., Satterlee, W., & Raber, M. N. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.491 · Cited by 759
Müller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., & Galle, P. R. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119174 · Cited by 748
Resveratrol: A review of preclinical studies for human cancer prevention
ATHAR, M., BACK, J., TANG, X., KIM, K., KOPELOVICH, L., BICKERS, D., & KIM, A. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.025 · Cited by 731
Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 683
Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together
Wang, T.-H., Wang, H.-S., & Soong, Y.-K. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2619::aid-cncr26>3.0.co;2-j · Cited by 647
Clinical Pharmacology of Resveratrol and Its Metabolites in Colorectal Cancer Patients
Patel, K. R., Brown, V. A., Jones, D. J. L., Britton, R. G., Hemingway, D., Miller, A. S., West, K. P., Booth, T. D., Perloff, M., Crowell, J. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2027 · Cited by 624
Cisplatin: From DNA damage to cancer chemotherapy
Cohen, S. M., & Lippard, S. J. (2001) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(01)67026-0 · Cited by 615
Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk196 · Cited by 612
Bcl2 is the guardian of microtubule integrity.
Haldar, S., Basu, A., & Croce, C. M. (1997) · PubMed · Cited by 599
Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0886 · Cited by 595
Resveratrol and health—A comprehensive review of human clinical trials
Smoliga, J. M., Baur, J. A., & Hausenblas, H. A. (2011) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100143 · Cited by 594
The 2004 World Health Organization classification of lung tumors
Beasley, M. B., Brambilla, E., & Travis, W. D. (2005) · Seminars in Roentgenology · doi:10.1053/j.ro.2005.01.001 · Cited by 564
Wei, Q. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.21.1764 · Cited by 507
Biological Effects of Resveratrol
Bhat, K. P. L., Kosmeder, J. W., & Pezzuto, J. M. (2001) · Antioxidants & Redox Signaling · doi:10.1089/152308601317203567 · Cited by 507
Wild‐Bode, C., Weller, M., Rimner, A., DICHGANS, J., & Wick, W. (2001) · PubMed · Cited by 464
Phase II Study of Taxol in Patients With Untreated Advanced Non-Small-Cell Lung Cancer
Murphy, W. K., Fossella, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.384 · Cited by 429
Cohen, M. H., Gootenberg, J., Keegan, P., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-713 · Cited by 396
Taxol: the first of the taxanes, an important new class of antitumor agents.
Rowinsky, E. K., Onetto-Pothier, N., Canetta, R. M., & Arbuck, S. G. (1992) · PubMed · Cited by 389
Cellular and molecular determinants of cisplatin resistance
Perez, R. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00227-5 · Cited by 384
Discodermolide, A Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol,
ter Haar, E., Kowalski, R. J., Hamel, E., Lin, C. M., Longley, R. E., Gunasekera, S. P., Rosenkranz, H. S., & Day, B. W. (1996) · Biochemistry · doi:10.1021/bi9515127 · Cited by 382
Mansouri, A., Ridgway, L. D., Korapati, A. L., Zhang, Q., Tian, L., Wang, Y., Siddik, Z. H., Mills, G. B., & Claret, F. X. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208134200 · Cited by 377
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review
Wang, L. G., Liu, X. M., Kreis, W., & Budman, D. R. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050989 · Cited by 373
Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., & Tanimoto, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.109 · Cited by 364
Chang, A. Y., Kim, K., Glick, J., Anderson, T., Karp, D., & Johnson, D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.388 · Cited by 336
Lu, J., Papp, L. V., Fang, J., Rodriguez-Nieto, S., Zhivotovsky, B., & Holmgren, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3310 · Cited by 326
Hsiao, W., & Liu, L. (2010) · Planta Medica · doi:10.1055/s-0030-1250186 · Cited by 302
Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2
Subbaramaiah, K., Hart, J. C., Norton, L., & Dannenberg, A. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.20.14838 · Cited by 300
McCubrey, J. A., Lertpiriyapong, K., Steelman, L. S., Abrams, S. L., Yang, L. V., Murata, R. M., Rosalen, P. L., Scalisi, A., Neri, L. M., Cocco, L., et al. (2017) · Aging · doi:10.18632/aging.101250 · Cited by 285
Le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R. M., Vansteenkiste, J., Thatcher, N., et al. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2004.10.014 · Cited by 277
Radiation therapy to a primary tumor accelerates metastatic growth in mice.
Camphausen, K. A., Moses, M. A., Beecken, W.-D. C., Khan, M. K., Folkman, J., & O’Reilly, M. S. (2001) · PubMed · Cited by 261
Zhu, J., Huang, J.-W., Tseng, P.-H., Yang, Y.-T., Fowble, J., Shiau, C.-W., Shaw, Y.-J., Kulp, S. K., & Chen, C.-S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-4063 · Cited by 258
Chen, C.-J., Liang, K.-Y., Chang, A.-S., Chang, Y.-C., Lu, S.-N., Liaw, Y.-F., Chang, W.-Y., Sheen, M.-C., & Lin, T.-M. (1991) · Hepatology · doi:10.1002/hep.1840130303 · Cited by 247
Pignon, J., & Stewart, L. A. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960601)77:11<2413::aid-cncr34>3.3.co;2-4 · Cited by 247
Preclinical Pharmacology of the Taxanes: Implications of the Differences
Gligorov, J., & Lotz, J. P. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_2-3 · Cited by 244
Perkins, C., Kim, C. N., Fang, G., & Bhalla, K. N. (2000) · Blood · doi:10.1182/blood.v95.3.1014.003k04_1014_1022 · Cited by 232
Bava, S. V., Puliappadamba, V. T., Deepti, A., Nair, A., Karunagaran, D., & Anto, R. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410647200 · Cited by 229
Ivanovska, N., & Philipov, S. (1996) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(96)00047-1 · Cited by 225
Taxol Induces Caspase-10-dependent Apoptosis
Park, S.-J., Wu, C.-H., Gordon, J. D., Zhong, X., Emami, A., & Safa, A. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406543200 · Cited by 198
Anderson, N. G., Ahmad, T., Chan, K., Dobson, R., & Bundred, N. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1557 · Cited by 197
Zhang, Q., Zhao, X.-H., & Wang, Z.-J. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.01.049 · Cited by 191
Cancer Epidemiology and Control in Taiwan: a Brief Review
Chen, C.-J., You, S.-L., Lin, L.-H., Hsu, W.-L., & Yang, Y.-W. (2002) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hye138 · Cited by 185
Anti-Inflammatory Plant Natural Products for Cancer Therapy
Kandan, A., & Yang, N. (2010) · Planta Medica · doi:10.1055/s-0030-1249859 · Cited by 172
Schiff, B. A., McMurphy, A. B., Jasser, S. A., Younes, M. N., Doan, D., Yigitbasi, O. G., Kim, S., Zhou, G., Mandal, M., Bekele, B. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0690 · Cited by 169
von Minckwitz, G., Jonat, W., Fasching, P., du Bois, A., Kleeberg, U., Lück, H.-J., Kettner, E., Hilfrich, J., Eiermann, W., Torode, J., et al. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-1720-2 · Cited by 167
Zhu, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.23.1745 · Cited by 166
Pasquier, E., Carré, M., Pourroy, B., Camoin, L., Rebaï, O., Briand, C., & Braguer, D. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1301.3.10 · Cited by 166
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Herbst, R. S., & Bunn, P. A. (2003) · PubMed · Cited by 162
Jung, J., Hwang, S.-Y., Hwang, J.-S., Oh, E., Park, S., & Han, I. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.01.034 · Cited by 159
Peng, P.-L., Hsieh, Y., Wang, C., Hsu, J., & Chou, F. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.11.010 · Cited by 155
Wang, K., Zhang, C., Bao, J., Jia, X., Liang, Y., Wang, X., Chen, M., Su, H., Li, P., Wan, J., et al. (2016) · Scientific Reports · doi:10.1038/srep26064 · Cited by 155
Chemoresistance in Non-Small Cell Lung Cancer
Sève, P., & Dumontet, C. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011053352604 · Cited by 149
Docetaxel enhances tumor radioresponse in vivo.
Mason, K. A., Hunter, N. R., Milas, M., Abbruzzese, J. L., & Milas, L. (1997) · PubMed · Cited by 149
DNA Repair: a Double-Edged Sword
Wei, Q., Frazier, M. L., & Levin, B. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.6.440 · Cited by 144
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Wang, Y., Schmid‐Bindert, G., & Zhou, C. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011427927 · Cited by 137
Lin, H.-L., Liu, T., Chau, G., Lui, W., & Chi, C. (2000) · Cancer · doi:10.1002/1097-0142(20000901)89:5<983::aid-cncr7>3.0.co;2-g · Cited by 137
Whyte, L., Huang, Y.-Y., Torres, K. E. O., & Mehta, R. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2464 · Cited by 135
Wang, Z. H., Kang, K. A., Zhang, R., Piao, M. J., Jo, S. H., Kim, J. S., Kang, S. S., Lee, J. S., Park, D. H., & Hyun, J. W. (2009) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2009.08.007 · Cited by 135
Ofir, R., Seidman, R., Rabinski, T., Krup, M., Yavelsky, V., Weinstein, Y., & Wolfson, M. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401012 · Cited by 129
Signal Transduction Pathways of Taxanes-Induced Apoptosis
Ganansia, V., Bischoff, P. L., Bergerat, J., et al. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033482422 · Cited by 128
Identification of Genes That Mediate Sensitivity to Cisplatin
Niedner, H., Christen, R. D., Lin, X., Kondo, A., & Howell, S. B. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1153 · Cited by 126
Chiang, P., Lin, S.-C., Pan, S., Kuo, C., Tsai, I., Kuo, M.-T., Wen, W., Chen, P., & Guh, J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.08.022 · Cited by 124
Read, W. L., Page, N. C., Tierney, R. M., Piccirillo, J. F., & Govindan, R. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.01.019 · Cited by 122
Shi, L., Tang, J., Li, T., & Liu, Z. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.016 · Cited by 122
S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells
Hennequin, C., Giocanti, N., & Favaudon, V. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.232 · Cited by 108
Stef, G., Csiszár, A., Lerea, K. M., Ungvari, Z. I., & Veress, G. (2006) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000238592.67191.ab · Cited by 101
A REVIEW ON THE CHEMICAL AND PHARMACOLOGICAL ASPECTS OF GENUSBERBERIS
Ikram, M. (1975) · Planta Medica · doi:10.1055/s-0028-1097869 · Cited by 98
Biochemical effects of berberine
Creasey, W. A. (1979) · Biochemical Pharmacology · doi:10.1016/0006-2952(79)90308-3 · Cited by 97
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours
Kucab, J. E., Lee, C., Chen, C., Zhu, J., Gilks, C. B., Cheang, M. C. U., Huntsman, D. D., Yorida, E., Emerman, J. T., Pollak, M., et al. (2005) · Breast Cancer Research · doi:10.1186/bcr1294 · Cited by 92
Mortality attributable to cigarette smoking in Taiwan: a 12-year follow-up study
Liaw, K.-M., & Chen, C. (1998) · Tobacco Control · doi:10.1136/tc.7.2.141 · Cited by 92
Li, F., Zhu, T., Cao, B., Wang, J., & Liang, L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.037 · Cited by 92
Yu, C., Chiang, P., Lu, P., Kuo, M.-T., Wen, W., Chen, P., & Guh, J. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2011.04.015 · Cited by 80
High-Throughput Screening of Natural Products for Cancer Therapy
Harvey, A. R., & Cree, I. A. (2010) · Planta Medica · doi:10.1055/s-0030-1250162 · Cited by 79
Park, S.-E., Yoo, H., Jin, C., Hong, S. H., Lee, Y.-W., Kim, B. W., Lee, S. H., Kim, W., Cho, C.-K., & Choi, Y. H. (2009) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.04.014 · Cited by 76
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer
Dhillon, S. (2015) · Targeted Oncology · doi:10.1007/s11523-015-0358-9 · Cited by 74
Kottke, T. J., Blajeski, A. L., Meng, X. W., Svingen, P. A., Ruchaud, S., Mesner, P. W., Boerner, S. A., Samejima, K., Henriquez, N. V., Chilcote, T. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108419200 · Cited by 73
Lacrima, K., Valentini, A., Lambertini, C., Taborelli, M., Rinaldi, A., Zucca, E., Catapano, C. V., Cavalli, F., Gianella-Borradori, A., MacCallum, D. E., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi217 · Cited by 72
Millward, M., Bishop, J., Friedlander, M. L., Levi, J. A., Goldstein, D., Olver, I. N., Smith, J., Toner, G. C., Rischin, D., & Bell, D. R. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.142 · Cited by 71
Tirado, Ò. M., Mateo‐Lozano, S., & Notario, V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1276 · Cited by 66
Han, S., Zhao, M.-B., Zhuang, G.-B., & Li, P.-P. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.06.001 · Cited by 65
Shi, Y., Sun, Y. P., Yu, J., Ding, C., Wang, Z., Wang, C., Wang, D., Wang, C., Wang, Z., Wang, M., et al. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12608 · Cited by 65
Self-citationHeinemann, V. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70021-3 · Cited by 62
Csóka, K., Liliemark, J. O., Larsson, R. L., & Nygren, P. (1995) · PubMed · Cited by 62
Accumulation of p53 and Reductions in XIAP Abundance Promote the Apoptosis of Prostate Cancer Cells
Mohapatra, S., Chu, B., Zhao, X., & Pledger, W. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0347 · Cited by 61
Lin, H.-C., Lin, M.-H., Liao, J., Wu, T., Lee, T., Mi, F., Wu, C., Chen, K., Cheng, C., & Lin, C. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04101 · Cited by 57
Enhancement of tumor radioresponse by docetaxel: Involvement of immune system
Mason, K. A., Staab, A., Hunter, N. R., McBride, W. H., Petersen, S. H., Terry, N. H. A., & Milas, L. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.3.599 · Cited by 55
Clinical impact of novel treatment strategies
Giaccone, G. (2002) · Oncogene · doi:10.1038/sj.onc.1205565 · Cited by 52
Li (2010) · Oncology Reports · doi:10.3892/or_00001034 · Cited by 51
Park, S., Kim, Y. M., & Pyo, H. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-222 · Cited by 44
Management of EGFR mutated nonsmall cell lung carcinoma patients
Grigoriu, B. D., Berghmans, T., & Meert, A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00156614 · Cited by 43
Protein Kinase Cα Mediates Erlotinib Resistance in Lung Cancer Cells
Abera, M. B., & Kazanietz, M. G. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.097725 · Cited by 43
Zhao, J. Y., Guerrero, A., Kelnar, K., Peltier, H. J., & Bader, A. G. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.020 · Cited by 43
The role of new agents in the treatment of non-small cell lung cancer
Bröker, L. E., & Giaccone, G. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00457-4 · Cited by 41
Patterns of lung cancer mortality in 23 countries: Application of the Age-Period-Cohort model
Liaw, Y., Huang, Y., & Lien, G. (2005) · BMC Public Health · doi:10.1186/1471-2458-5-22 · Cited by 37
Pancreatic Cancer: Medical Management (Novel Chemotherapeutics)
Páez, D., LaBonte, M. J., & Lenz, H. (2012) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.12.004 · Cited by 36
Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer
Belani, C. P. (2000) · CHEST Journal · doi:10.1378/chest.117.4_suppl_1.144s · Cited by 31
Erten, Ç., Demir, L., Somali, I., Alacacıoğlu, A., Küçükzeybek, Y., Akyol, M., Can, A., Dirican, A., Bayoğlu, İ. V., & Tarhan, M. O. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.6.3711 · Cited by 31
ZHANG, F., Zhang, T., Gu, Z., Zhou, Y., Han, Y. H., Li, X., Wang, X., Cheng, Q., & Mei, Q. (2008) · Journal of Radiation Research · doi:10.1269/jrr.08024 · Cited by 31
Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Gatzemeier, U., Heckmayer, M., Neuhauss, R., Schlüter, I., von Pawel, J., Wagner, H., & Dreps, A. (1995) · PubMed · Cited by 28
Kim, M., Chin, Y., & Lee, E. J. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.074 · Cited by 27
Tong, Z., Wu, X., Chen, C., & Kehrer, J. P. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2005.12.003 · Cited by 25
Mahalingam, D., Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.03.001 · Cited by 23
[Anti-blastic properties of berberine and its derivatives].
Shvarev, I. F., & Tsetlin, A. L. (1972) · PubMed · Cited by 8
Lee (2012) · Journal of Clinical Medicine Research · doi:10.4021/jocmr816e · Cited by 7
Cited by
Emerging trends in the novel drug delivery approaches for the treatment of lung cancer
Sharma, P., Mehta, M., Dhanjal, D. S., Kaur, S., Gupta, G., Singh, H., Thangavelu, L., Rajeshkumar, S., Tambuwala, M., Bakshi, H. A., et al. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.06.033 · Cited by 430
Myricetin: A review of the most recent research
Song, X., Tan, L., Wang, M., Ren, C., Guo, C., Yang, B., Ren, Y., Cao, Z., Li, Y., & Pei, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111017 · Cited by 378
Microalgae: therapeutic potentials and applications
Khavari, F., Saidijam, M., Taheri, M., & Nouri, F. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06422-w · Cited by 257
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Metadata
- Authors
- Huang, C.-Y., Ju, D.-T., Chang, C.-F., Muralidhar Reddy, P., & Velmurugan, B. K.
- Venue
- BioMedicine
- Publisher
- China Medical University
- Published
- 2017-11-24
- Volume
- 7
- Issue
- 4
- Pages
- 23
- ISSN
- 2211-8020 (ISSN-L)
- 2211-8039
- OpenAlex
- W2768610432
- Cited by
- 481
- References
- 131
- FWCI
- 29.77
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.